Core Insights - Elutia Inc. has appointed Guido J. Neels to its Board of Directors, who will also serve on the audit committee, following the resignation of W. Matthew Zuga and Maybelle Jordan from the Board [1][2] Company Overview - Elutia is a pioneer in drug-eluting biomatrix technologies, focusing on improving compatibility between medical devices and patients [4] - The company aims to humanize medicine, allowing patients to thrive without compromise, particularly in the context of a growing population needing implantable technologies [4] Leadership Experience - Guido J. Neels brings over 40 years of experience in the medical technology sector, having held various managerial and strategic roles [2] - Neels is currently an Operating Partner at EW Healthcare Partners and has been instrumental in building EW's medical device investment practice [2] - His previous roles include Chief Operating Officer at Guidant Corporation, where he oversaw multiple operating units and was responsible for sales operations and corporate communications [3] Strategic Direction - Neels expressed his honor in joining Elutia during a pivotal moment for the company, emphasizing the potential of Elutia's technology to improve patient outcomes and drive innovation in breast reconstruction [4] - The company is focused on leveraging its drug-eluting biomatrix technology to build significant shareholder value, especially following the recent divestiture of its EluPro business [2]